Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinflunine in Relapsed Extensive Small Cell Lung Cancer
NCT00284154Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jan 2006
- Primary completion
- May 2009
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinflunine in small cell lung cancer (SCLC), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate at 18 months. Started Jan 2006; status: completed.
02
Drugs
vinflunine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00284154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00284154.